<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38508">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01920022</url>
  </required_header>
  <id_info>
    <org_study_id>QW2013</org_study_id>
    <nct_id>NCT01920022</nct_id>
  </id_info>
  <brief_title>Quickstart of Nexplanon® at Medical Abortion</brief_title>
  <official_title>Early Versus Delayed Insertion of Nexplanon® at Medical Abortion - a Randomized Controlled Equivalence Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <authority>Sweden: Medical Products Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women having abortions are at high risk for subsequent unintended pregnancy and repeat
      abortion. Clearly, encouraging contraceptive use after abortion is a high priority. Long
      acting reversible contraceptives (LARCs, Implants and intrauterine contraception) are the
      most effective methods to help women avoid a repeat unwanted pregnancy and abortion. Studies
      in surgical abortion patients, show that &quot;quickstart&quot; of a LARC - i.e., inserting it during
      the surgical procedure - is associated with substantially greater use of that method six
      months later than requiring women to return later to get the device. However, today a
      majority of women chose medical abortion. The clinical routine is to insert LARCs at the
      follow up 2 to 3 weeks after the abortion treatment. Frequently women choose to do part of
      the abortion treatment at home and do not return for a follow up. Thus, the possibility to
      quick start a contraceptive method in medical abortion would be a major advantage especially
      if this could be done at the time of administration of mifepristone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Complete abortions without surgical intervention</measure>
    <time_frame>at 3 weeks follow up</time_frame>
    <safety_issue>No</safety_issue>
    <description>Efficacy of the medical abortion treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unplanned pregnancy</measure>
    <time_frame>during one year FU</time_frame>
    <safety_issue>No</safety_issue>
    <description>Numbers of pregnancies within the first year following the index abortion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of women with complications</measure>
    <time_frame>evaluated at the 3weeks FU</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>reports and rates of AE/SAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of implant insertion</measure>
    <time_frame>up to 1year FU</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compliance, contraceptive usage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>Evaluated at 1 year FU</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Bleeding will be evaluated  with regard to both bleeding during the medical abortion and bleeding patterns during the one year FU</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">560</enrollment>
  <condition>Early Pregnancy Termination</condition>
  <condition>Medical Abortion</condition>
  <condition>Postabortion Contraception</condition>
  <arm_group>
    <arm_group_label>Etonorgestrel and mifepristone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quickstart, insertion of Nexplanon on the day of mifepristone in medical abortion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mifepristone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mifepristone on day 1. Nexplanon insertion at 3 weeks FU after the medical abortion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <description>Day one of medical abortion</description>
    <arm_group_label>Etonorgestrel and mifepristone</arm_group_label>
    <arm_group_label>mifepristone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etonorgestrel</intervention_name>
    <arm_group_label>Etonorgestrel and mifepristone</arm_group_label>
    <other_name>Nexplanon, Contraceptive implant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women opting for medical abortion and post abortion Nexplanon

          -  no contraindicated to medical abortion or Nexplanon (according to the SMPc)
             gestational length up to and including 63 days (determined with ultrasonography)

          -  able and willing to provide informed consent

        Exclusion Criteria:

          -  unwilling to participate,

          -  unable to communicate in Swedish and English and

          -  minors (i.e. women &lt; 18 years of age),

          -  contraindications to Nexplanon®

          -  women with pathological pregnancies
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristina Gemzell-Danielsson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristina Gemzell-Danielsson, MD, PhD</last_name>
    <phone>+46851772128</phone>
    <email>kristina.gemzell@ki.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset/Östra</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Helena Hognert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jan Brynhildsen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christina Nyrelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kristina Gemzell-Danielsson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Danderyds Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Helena Kopp Kallner, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset i Örebro</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Izabella Jawad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chalmers Sexual and Reproductive Health Service</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH3 9ES</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sharon Cameron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 19, 2013</lastchanged_date>
  <firstreceived_date>August 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Kristina Gemzell Danielsson</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>medical abortion</keyword>
  <keyword>postabortion contraception</keyword>
  <keyword>LARC</keyword>
  <keyword>Nexplanon</keyword>
  <keyword>subdermal contraceptive implant</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
    <mesh_term>3-keto-desogestrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
